These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 29532161)

  • 1. Higher Sclerostin/SOST expression is associated with lower percentage of circulatory blasts and better prognosis in patients with myelofibrosis.
    Lucijanic M; Livun A; Tupek KM; Stoos-Veic T; Pejsa V; Kusec R
    Ann Hematol; 2018 Jul; 97(7):1293-1294. PubMed ID: 29532161
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis.
    Lucijanic M; Mitrovic Z; Cicic D; Prka Z; Pejsa V; Livun A; Stoos-Veic T; Romic Z; Zivkovic M; Lucijanic I; Fabris Z; Kusec R
    Int J Hematol; 2018 Feb; 107(2):166-172. PubMed ID: 29022201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation regulates sclerostin (SOST) expression in osteoarthritic chondrocytes by bone morphogenetic protein 2 (BMP-2) induced changes in Smads binding affinity to the CpG region of SOST promoter.
    Papathanasiou I; Kostopoulou F; Malizos KN; Tsezou A
    Arthritis Res Ther; 2015 Jun; 17(1):160. PubMed ID: 26071314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of the SOST bone enhancer by PTH using MEF2 transcription factors.
    Leupin O; Kramer I; Collette NM; Loots GG; Natt F; Kneissel M; Keller H
    J Bone Miner Res; 2007 Dec; 22(12):1957-67. PubMed ID: 17696759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia.
    Hernández-Boluda JC; Correa JG; Alvarez-Larrán A; Ferrer-Marín F; Raya JM; Martínez-López J; Velez P; Pérez-Encinas M; Estrada N; García-Gutiérrez V; Fox ML; Luño E; Kerguelen A; Cuevas B; Durán MA; Ramírez MJ; Gómez-Casares M; Mata-Vázquez MI; Regadera A; Pereira A; Cervantes F;
    Br J Haematol; 2018 May; 181(3):397-400. PubMed ID: 28419426
    [No Abstract]   [Full Text] [Related]  

  • 6. Variations of SOST mRNA expression in human bone are associated with DNA polymorphism and DNA methylation in the SOST gene.
    Lhaneche L; Hald JD; Domingues A; Hannouche D; Delepine M; Zelenika D; Boland A; Ostertag A; Cohen-Solal M; Langdahl BL; Harsløf T; de Vernejoul MC; Geoffroy V; Jehan F
    Bone; 2016 Nov; 92():107-115. PubMed ID: 27519970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis.
    Barbui T; Carobbio A; Finazzi G; Guglielmelli P; Salmoiraghi S; Rosti V; Rambaldi A; Vannucchi AM; Barosi G
    Leukemia; 2013 Oct; 27(10):2084-6. PubMed ID: 23828261
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of GSK3β Stimulates BMP Signaling and Decreases SOST Expression Which Results in Enhanced Osteoblast Differentiation.
    Schoeman MA; Moester MJ; Oostlander AE; Kaijzel EL; Valstar ER; Nelissen RG; Löwik CW; de Rooij KE
    J Cell Biochem; 2015 Dec; 116(12):2938-46. PubMed ID: 26095393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implications of low transferrin saturation in patients with primary myelofibrosis.
    Lucijanic M; Prka Z; Pejsa V; Stoos-Veic T; Lucijanic J; Kusec R
    Leuk Res; 2018 Mar; 66():89-95. PubMed ID: 29407589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women.
    Reppe S; Noer A; Grimholt RM; Halldórsson BV; Medina-Gomez C; Gautvik VT; Olstad OK; Berg JP; Datta H; Estrada K; Hofman A; Uitterlinden AG; Rivadeneira F; Lyle R; Collas P; Gautvik KM
    J Bone Miner Res; 2015 Feb; 30(2):249-56. PubMed ID: 25155887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow fibrosis at diagnosis is associated with TP53 overexpression and adverse prognosis in low-risk myelodysplastic syndrome.
    Duarte FB; Barbosa MC; Jesus Dos Santos TE; Lemes RPG; Vasconcelos JP; de Vasconcelos PRL; Rocha FD; Zalcberg I; Coutinho DF
    Br J Haematol; 2018 May; 181(4):547-549. PubMed ID: 28318026
    [No Abstract]   [Full Text] [Related]  

  • 12. A Sclerostin super-producer cell line derived from the human cell line SaOS-2: a new tool for the study of the molecular mechanisms driving Sclerostin expression.
    Pérez-Campo FM; Sañudo C; Delgado-Calle J; Arozamena J; Zarrabeitia MT; Riancho JA
    Calcif Tissue Int; 2014 Aug; 95(2):194-9. PubMed ID: 24913258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1α,25-dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretion.
    Wijenayaka AR; Yang D; Prideaux M; Ito N; Kogawa M; Anderson PH; Morris HA; Solomon LB; Loots GG; Findlay DM; Atkins GJ
    Mol Cell Endocrinol; 2015 Sep; 413():157-67. PubMed ID: 26112182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls.
    van Lierop AH; Witteveen JE; Hamdy NA; Papapoulos SE
    Eur J Endocrinol; 2010 Nov; 163(5):833-7. PubMed ID: 20817762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low sirtuin 1 levels in human osteoarthritis subchondral osteoblasts lead to abnormal sclerostin expression which decreases Wnt/β-catenin activity.
    Abed É; Couchourel D; Delalandre A; Duval N; Pelletier JP; Martel-Pelletier J; Lajeunesse D
    Bone; 2014 Feb; 59():28-36. PubMed ID: 24184155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rat Osteosarcoma Cells as a Therapeutic Target Model for Osteoregeneration via Sclerostin Knockdown.
    Sedaghati B; Jahroomishirazi R; Starke A; Hacker MC; Schulz-Siegmund M
    Cells Tissues Organs; 2016; 201(5):366-79. PubMed ID: 27233518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High absolute basophil count is a powerful independent predictor of inferior overall survival in patients with primary myelofibrosis.
    Lucijanic M; Livun A; Stoos-Veic T; Pejsa V; Jaksic O; Cicic D; Lucijanic J; Romic Z; Orehovec B; Aralica G; Miletic M; Kusec R
    Hematology; 2018 May; 23(4):201-207. PubMed ID: 28906207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paradoxical response to mechanical unloading in bone loss, microarchitecture, and bone turnover markers.
    Sun X; Yang K; Wang C; Cao S; Merritt M; Hu Y; Xu X
    Int J Med Sci; 2015; 12(3):270-9. PubMed ID: 25798053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels.
    Tefferi A; Nicolosi M; Penna D; Mudireddy M; Szuber N; Lasho TL; Hanson CA; Ketterling RP; Gangat N; Pardanani AD
    Blood Adv; 2018 Aug; 2(15):1980-1984. PubMed ID: 30097464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen Modulates Bone Morphogenetic Protein-Induced Sclerostin Expression Through the Wnt Signaling Pathway.
    Kim RY; Yang HJ; Song YM; Kim IS; Hwang SJ
    Tissue Eng Part A; 2015 Jul; 21(13-14):2076-88. PubMed ID: 25837159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.